1. Complement as a source of biomarkers in systemic lupus erythematosus: Past, present, and future

   • Chau-Ching Liu
   • Joseph M. Ahearn
   • Susan Manzi

   Invited Commentary Pages: 85 - 88

2. Web alert

   News Pages: 89 - 90

3. Literature alert

   Abstract Pages: 91 - 92

4. The efficacy of etanercept in ankylosing spondylitis

   • Christopher T. Ritchlin

   Clinical Trials Report Pages: 95 - 95

5. The efficacy of etanercept in ankylosing spondylitis

   • Christopher T. Ritchlin

   Clinical Trials Report Pages: 95 - 96

6. The efficacy of infliximab in ankylosing spondylitis

   • Christopher T. Ritchlin

   Clinical Trials Report Pages: 96 - 96

7. Treatment guidelines for ankylosing spondylitis

   • Christopher T. Ritchlin

   Clinical Trials Report Pages: 96 - 97

8. New directions in classification and outcome assessment in ankylosing spondylitis

   • Désirée van der Heijde

   OriginalPaper Pages: 98 - 101

9. Imaging in spondyloarthropathies

   • Mikayel Grigoryan
   • Frank W. Roemer
   • Harry K. Genant

   OriginalPaper Pages: 102 - 109

10. Disease mechanisms in reactive arthritis

    • Joachim Sieper

    OriginalPaper Pages: 110 - 116

11. The genetic basis of spondyloarthritis

    • John D. Reveille

    OriginalPaper Pages: 117 - 125

12. Scleroderma renal crisis: New insights and developments

    • Elisa Y. Rhew
    • Walter G. Barr

    OriginalPaper Pages: 129 - 136

13. The heart in systemic sclerosis

    • Virginia Steen

    OriginalPaper Pages: 137 - 140

14. The pathogenesis of fibrosis and renal disease in scleroderma: Recent insights from glomerulosclerosis

    • Sungchun Lee
    • Sohee Lee
    • Kumar Sharma

    OriginalPaper Pages: 141 - 148

15. Vascular injury in systemic sclerosis: Angiotensin-converting enzyme insertion/deletion polymorphism

    • Cinzia Fatini
    • Serena Guiducci
    • Marco Matucci-Cerinic

    OriginalPaper Pages: 149 - 155

16. Antibodies in scleroderma: Direct pathogenicity and phenotypic associations

    • Lorinda Chung
    • Paul J. Utz

    OriginalPaper Pages: 156 - 163

17. Antifibrotic therapy in scleroderma: Extracellular or intracellular targeting of activated fibroblasts?

    • John Varga

    OriginalPaper Pages: 164 - 170